Wilsey Asset Management Inc. Acquires Shares of 360,753 Zimmer Biomet Holdings, Inc. $ZBH

Wilsey Asset Management Inc. bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 360,753 shares of the medical equipment provider’s stock, valued at approximately $32,439,000. Zimmer Biomet comprises approximately 5.0% of Wilsey Asset Management Inc.’s investment portfolio, making the stock its 11th largest holding.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC purchased a new position in Zimmer Biomet during the fourth quarter worth approximately $204,000. Sivia Capital Partners LLC purchased a new position in shares of Zimmer Biomet during the 2nd quarter valued at approximately $232,000. United Bank lifted its position in shares of Zimmer Biomet by 10.7% during the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock valued at $1,085,000 after buying an additional 1,153 shares in the last quarter. Creative Planning grew its stake in Zimmer Biomet by 24.1% in the 2nd quarter. Creative Planning now owns 31,445 shares of the medical equipment provider’s stock valued at $2,868,000 after acquiring an additional 6,105 shares during the period. Finally, Nomura Asset Management Co. Ltd. increased its holdings in Zimmer Biomet by 0.7% in the 2nd quarter. Nomura Asset Management Co. Ltd. now owns 65,162 shares of the medical equipment provider’s stock worth $5,943,000 after acquiring an additional 472 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.39% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on ZBH. Wells Fargo & Company lifted their target price on shares of Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 11th. Sanford C. Bernstein lifted their price objective on Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a report on Friday, January 9th. Barclays cut their price objective on Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating for the company in a research note on Thursday, February 12th. Evercore raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their price target for the stock from $94.00 to $120.00 in a research note on Monday, January 5th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $106.20.

Zimmer Biomet Trading Down 2.0%

Shares of Zimmer Biomet stock opened at $88.04 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. The stock’s 50 day simple moving average is $92.12 and its 200-day simple moving average is $94.73. The stock has a market cap of $17.23 billion, a P/E ratio of 24.87, a P/E/G ratio of 1.83 and a beta of 0.58. Zimmer Biomet Holdings, Inc. has a 1-year low of $84.59 and a 1-year high of $114.44.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The firm had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm’s revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio is currently 27.12%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.